Skip to main content

Random Plasma Glucose in Serendipitous Screening for Glucose Intolerance: Screening for Impaired Glucose Tolerance Study 2

Journal of General Internal Medicine volume 23, pages 528–535 (2008)Cite this article

Abstract

Background

With positive results from diabetes prevention studies, there is interest in convenient ways to incorporate screening for glucose intolerance into routine care and to limit the need for fasting diagnostic tests.

Objective

The aim of this study is to determine whether random plasma glucose (RPG) could be used to screen for glucose intolerance.

Design

This is a cross-sectional study.

Participants

The participants of this study include a voluntary sample of 990 adults not known to have diabetes.

Measurements

RPG was measured, and each subject had a 75-g oral glucose tolerance test several weeks later. Glucose intolerance targets included diabetes, impaired glucose tolerance (IGT), and impaired fasting glucose110 (IFG110; fasting glucose, 110–125 mg/dl, and 2 h glucose < 140 mg/dl). Screening performance was measured by area under receiver operating characteristic curves (AROC).

Results

Mean age was 48 years, and body mass index (BMI) was 30.4 kg/m2; 66% were women, and 52% were black; 5.1% had previously unrecognized diabetes, and 24.0% had any “high-risk” glucose intolerance (diabetes or IGT or IFG110). The AROC was 0.80 (95% CI 0.74–0.86) for RPG to identify diabetes and 0.72 (0.68–0.75) to identify any glucose intolerance, both highly significant (p < 0.001). Screening performance was generally consistent at different times of the day, regardless of meal status, and across a range of risk factors such as age, BMI, high density lipoprotein cholesterol, triglycerides, and blood pressure.

Conclusions

RPG values should be considered by health care providers to be an opportunistic initial screening test and used to prompt further evaluation of patients at risk of glucose intolerance. Such “serendipitous screening” could help to identify unrecognized diabetes and prediabetes.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Figure 1
Figure 2

Abbreviations

ARIC:

Atherosclerosis Risk in Communities

NHANES-III:

National Health and Nutrition Examination Survey III

AGT110 :

any glucose intolerance110 (dysglycemia)

T2DM:

type 2 diabetes mellitus

ROC:

receiver-operating-characteristic

AROC:

area under the ROC curve

IGT:

impaired glucose tolerance

IFG:

impaired fasting glucose

IFG110 or IFG110–125 :

IFG with fasting plasma glucose 110–125 mg/dl

Dysglycemia:

type 2 diabetes or IGT or IFG110

WHO:

World Health Organization

NCEP:

National Cholesterol Education Program

HDL:

high density lipoprotein

References

  1. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005–2050. Diabetes Care. 2006;29:2114–6.

    PubMed  Article  Google Scholar 

  2. Harris MI. Diabetes in America: epidemiology and scope of the problem. Diabetes Care. 1998;21:C11–4.

    PubMed  Google Scholar 

  3. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290:1884–90.

    PubMed  Article  CAS  Google Scholar 

  4. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003;26:917–32.

    Article  Google Scholar 

  5. Brown JB, Nichols GA, Glauber HS, Bakst AW. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care. 1999;22:1116–24.

    PubMed  Article  CAS  Google Scholar 

  6. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care. 1992;15:815–9.

    PubMed  Article  CAS  Google Scholar 

  7. Thompson TJ, Engelgau MM, Hegazy M, Ali MA, Sous ES, Badran A, et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med. 1996;13:337–40.

    PubMed  Article  CAS  Google Scholar 

  8. Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, Matthews DR, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol. 2000;116:297–303.

    Google Scholar 

  9. Goldschmid MG, Domin WS, Ziemer DC, Gallina DL, Phillips LS. Diabetes in Urban African-Americans. II. High prevalence of microalbuminuria and nephropathy in African-Americans with diabetes. Diabetes Care. 1995;18:955–61.

    PubMed  Article  CAS  Google Scholar 

  10. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323–32.

    PubMed  Google Scholar 

  11. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

    Article  Google Scholar 

  12. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–10.

    PubMed  Article  CAS  Google Scholar 

  13. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335–42.

    PubMed  Article  CAS  Google Scholar 

  14. Saaddine JB, Cadwell B, Gregg EW, Engelgau MM, Vinicor F, Imperatore G, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann Intern Med. 2006;144:465–74.

    PubMed  Google Scholar 

  15. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care. 2006;29:504–9.

    PubMed  Article  CAS  Google Scholar 

  16. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.

    Article  Google Scholar 

  17. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–105.

    PubMed  Article  CAS  Google Scholar 

  18. American Diabetes Association, NIH/NIDDK. The prevention or delay of type 2 diabetes. Diab Care. 2002;25:742–9.

    Article  Google Scholar 

  19. Ealovega MW, Tabaei BP, Brandle M, Burke R, Herman WH. Opportunistic screening for diabetes in routine clinical practice. Diabetes Care. 2004;27:9–12.

    PubMed  Article  Google Scholar 

  20. Leiter LA, Barr A, Belanger A, Lubin S, Ross SA, Tildesley HD, et al. Diabetes screening in Canada (DIASCAN) study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. Diabetes Care. 2001;24:1038–43.

    PubMed  Article  CAS  Google Scholar 

  21. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28(Suppl 1):S37–42.

    Article  Google Scholar 

  22. American Heart Association. http://www.americanheart.org/presenter.jhtml?identifier = 4756. Accessed 10 January 2008.

  23. Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care. 2005;28:2626–32.

    PubMed  Article  Google Scholar 

  24. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Bittner V, Cauley JA, et al. Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. Ann Intern Med. 2005;142:813–20.

    PubMed  Google Scholar 

  25. Harrell FE Jr. Regression modeling strategies with applications to linear models, logistic regression and survival analysis. New York: Springer; 2001.

    Google Scholar 

  26. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA. 1998;280:1757–63.

    Article  Google Scholar 

  27. Shavelle DM, Budoff MJ, Lamont DH, Shavelle RM, Kennedy JM, Brundage BH. Exercise testing and electron beam computed tomography in the evaluation of coronary artery disease. J Am Coll Cardiol. 2000;36:32–8.

    PubMed  Article  CAS  Google Scholar 

  28. West KM, Kalbfleisch JM. Sensitivity and specificity of five screening tests for diabetes in ten countries. Diabetes. 1971;20:289–96.

    PubMed  CAS  Google Scholar 

  29. Hilton DJ, Welborn TA, O’Rourke PK, Reid CM. Forget to fast. Diabetes Care. 2002;25:2122.

    Article  Google Scholar 

  30. Welborn TA, Reid CM, Marriott G. Australian Diabetes Screening Study: impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism. 1997;46:35–9.

    PubMed  Article  CAS  Google Scholar 

  31. Johnson SL, Tabaei BP, Herman WH. The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45–74 years of age. Diabetes Care. 2005;28:307–11.

    PubMed  Article  Google Scholar 

  32. Zhang P, Engelgau MM, Valdez R, Cadwell B, Benjamin SM, Narayan KMV. Efficient cutoff points for three screening tests for detecting undiagnosed diabetes and pre-diabetes: an economic analysis. Diabetes Care. 2005;28:1321–5.

    PubMed  Article  Google Scholar 

  33. Rolka DB, Narayan KMV, Thompson TJ, Goldman D, Lindenmayer J, Alich K, et al. Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care. 2001;24:1899–903.

    PubMed  Article  CAS  Google Scholar 

  34. Engelgau MM, Thompson TJ, Smith PJ, Herman WH, Aubert RE, Gunter EW, et al. Screening for diabetes mellitus in adults: the utility of random capillary blood glucose measurements. Diabetes Care. 1995;18:463–6.

    PubMed  Article  CAS  Google Scholar 

  35. Tabaei BP, Herman WH. A multivariate logistic regression equation to screen for diabetes: development and validation. Diabetes Care. 2002;25:1999–2003.

    PubMed  Article  Google Scholar 

  36. Lindstrom J, Tuomilehto J. The diabetes risk score. Diabetes Care. 2003;26:725–31.

    PubMed  Article  Google Scholar 

  37. Glümer C, Carstensen B, Sandbæk A, Lauritzen T, Jørgensen T, Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care. 2004;27:727–33.

    PubMed  Article  Google Scholar 

  38. Schulze MB, Hoffmann K, Boeing H, Linseisen J, Rohrmann S, Mohlig M, et al. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care. 2007;30:510–15.

    PubMed  Article  Google Scholar 

  39. Spijkerman AMW, Yuyun MF, Griffin SJ, Dekker JM, Nijpels G, Wareham NJ. The performance of a risk score as a screening test for undiagnosed hyperglycemia in ethnic minority groups: data from the 1999 health survey for England. Diabetes Care. 2004;27:116–22.

    PubMed  Article  Google Scholar 

  40. Franciosi M, De BG, Rossi MC, Sacco M, Belfiglio M, Pellegrini F, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care. 2005;28:1187–94.

    PubMed  Article  Google Scholar 

  41. Aekplakorn W, Bunnag P, Woodward M, Sritara P, Cheepudomwit S, Yamwong S, et al. A risk score for predicting incident diabetes in the Thai population. Diabetes Care. 2006;29:1872–77.

    PubMed  Article  Google Scholar 

  42. Ruige JB, De Neeling JND, Kostense PJ, Bouter LM, Heine RJ. Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care. 1997;20:491–6.

    PubMed  Article  CAS  Google Scholar 

  43. Screening for Type 2 Diabetes Mellitus. AHRQ Systematic Evidence Review number 19. http://www.ahrq.gov/downloads/pub/prevent/pdfser/diabser.pdf. Accessed 28 February 2007.

  44. Samuels TA, Cohen D, Brancati FL, Coresh J, Kao WHL. Delayed diagnosis of incident type 2 diabetes mellitus in the ARIC study. Am J Manag Care. 2006;12:717–24.

    PubMed  Google Scholar 

  45. Thaler LM, El-Kebbi IM, Ziemer DC, Gallina DL, Dunbar VG, Phillips LS. High prevalence of albuminuria among African-Americans with short duration of diabetes. Diabetes Care. 1998;21:1576–7.

    PubMed  Article  CAS  Google Scholar 

  46. Henricsson M, Nyström L, Blohmé G, Östman J, Kullberg C, Svemsson M, et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care. 2003;26:349–54.

    PubMed  Article  Google Scholar 

  47. Smith NL, Barzilay JI, Kronmal R, Lumley T, Enquobahrie D, Psaty BM. New-onset diabetes and risk of all-cause and cardiovascular mortality: the Cardiovascular Health Study. Diabetes Care. 2006;29:2012–17.

    PubMed  Article  Google Scholar 

  48. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129–34.

    PubMed  Article  Google Scholar 

  49. Gulliford MC, Charlton J, Latinovic R. Increased utilization of primary care 5 years before diagnosis of type 2 diabetes: a matched cohort study. Diabetes Care. 2005;28:47–52.

    PubMed  Article  Google Scholar 

  50. Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis. Diabetes Care. 2000;23:1654–9.

    PubMed  Article  CAS  Google Scholar 

  51. Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. Prospective Diabetes Study 61. Diabetes Care. 2002;25:1410–7.

    PubMed  Article  Google Scholar 

  52. Festa A, Williams K, D’Agostino R Jr., Wagenknecht LE, Haffner SM. The natural course of {beta}-cell function in nondiabetic and diabetic individuals: The Insulin Resistance Atherosclerosis Study. Diabetes. 2006;55:1114–20.

    PubMed  Article  CAS  Google Scholar 

  53. Xiang AH, Wang C, Peters RK, Trigo E, Kjos SL, Buchanan TA. Coordinate changes in plasma glucose and pancreatic {beta}-cell function in Latino women at high risk for type 2 diabetes. Diabetes. 2006;55:1074–9.

    PubMed  Article  CAS  Google Scholar 

  54. Phillips LS, Branch WT Jr., Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Int Med. 2001;135:825–34.

    PubMed  CAS  Google Scholar 

  55. Brown JB, Nichols GA. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care. 2003;9:213–7.

    PubMed  Google Scholar 

  56. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005;28:995–1000.

    PubMed  Article  CAS  Google Scholar 

  57. Cowie CC, Harris MI, Eberhardt MS. Frequency and determinants of screening for diabetes in the U.S. Diabetes Care. 1994;17:1158–63.

    PubMed  Article  CAS  Google Scholar 

  58. Clark HD, van Walraven C, Code C, Karovitch A, Keely E. Did publication of a clinical practice guideline recommendation to screen for type 2 diabetes in women with gestational diabetes change practice. Diabetes Care. 2003;26:265–8.

    PubMed  Article  Google Scholar 

  59. CMS Clinical Laboratory Fee Schedule—December 1, 2006. http://www.cms.hhs.gov/ClinicalLabFeeSched/02_clinlab.asp. Accessed 28 February 2007.

  60. Zhang P, Engelgau MM, Valdez , Benjamin SM, Cadwell B, Narayan KMV. Costs of screening for pre-diabetes among U.S. adults. Diabetes Care. 2003;26:2536–42.

    PubMed  Article  Google Scholar 

  61. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med. 2004;140:689–99.

    PubMed  Google Scholar 

  62. Hilton DJ, O’Rourke PK, Welborn TA, Reid CM. Diabetes detection in Australian general practice: a comparison of diagnostic criteria. Med J Aust. 2002;176:104–7.

    PubMed  Google Scholar 

  63. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little R, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. A third national nutrition examination study, 1988–1994. Diabetes Care. 1998;21:518–24.

    PubMed  Article  CAS  Google Scholar 

  64. Centers for Disease Control and Prevention (CDC). Prevalence of diabetes and impaired fasting glucose in adults—United States, 1999–2000. MMWR. 2003;52:833–7.

    Google Scholar 

  65. CDC National Diabetes Fact Sheet; 2002. http://www.cdc.gov/diabetes/pubs/estimates.htm. Accessed 28 February 2007.

Download references

Acknowledgment

This work was supported in part by DK07298, DK062668, RR017643, DK066204, and RR00039. We thank Jane Caudle, Jack Kaufman, Eileen Osinski, Elizabeth Barrera, Jade Irving, and Aisha Bobcombe for their assistance. Portions of this work were presented at the Scientific Sessions of the American Diabetes Association in Washington, DC (2006).

Conflict of interest Statement

None disclosed.

Author information

Author notes

  1. Paul Kolm PhD & William S. Weintraub MD

    Present address: Christiana Care Health System, Newark, DE, USA

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Emory University School of Medicine, Atlanta, GA, USA

    David C. Ziemer MD, Mary K. Rhee MD, MS, Rincy M. Varughese MS, Circe W. Tsui BBA & Lawrence S. Phillips MD

  2. Cardiology, Emory University School of Medicine, Atlanta, GA, USA

    Paul Kolm PhD, Jovonne K. Foster MS, William S. Weintraub MD & Viola Vaccarino MD, PhD

  3. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA

    David D. Koch PhD

  4. Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA

    Jennifer G. Twombly MD, PhD & K. M. Venkat Narayan MD, MPH, MBA

  5. Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA

    K. M. Venkat Narayan MD, MPH, MBA

  6. VA Medical Center, Atlanta, GA, USA

    Lawrence S. Phillips MD

  7. Division of Endocrinology, Emory University, Atlanta, GA, USA

    Lawrence S. Phillips MD

Authors
  1. David C. Ziemer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Kolm PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jovonne K. Foster MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William S. Weintraub MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Viola Vaccarino MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mary K. Rhee MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rincy M. Varughese MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Circe W. Tsui BBA
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. David D. Koch PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jennifer G. Twombly MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. K. M. Venkat Narayan MD, MPH, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Lawrence S. Phillips MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lawrence S. Phillips MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ziemer, D.C., Kolm, P., Foster, J.K. et al. Random Plasma Glucose in Serendipitous Screening for Glucose Intolerance: Screening for Impaired Glucose Tolerance Study 2. J GEN INTERN MED 23, 528–535 (2008). https://doi.org/10.1007/s11606-008-0524-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11606-008-0524-1

KEY WORDS

  • type 2 diabetes
  • prediabetes
  • impaired glucose intolerance
  • impaired fasting glucose
  • screening